Morgan Stanley initiated coverage on 4D Molecular Therapeutics with a new price target

11/21/24 7:33:52 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Morgan Stanley initiated coverage of 4D Molecular Therapeutics with a rating of Underweight and set a new price target of $8.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FDMT

Date	Price Target	Rating	Analyst
1/13/2025	$40.00 → $15.00	Outperform → Market Perform	BMO Capital Markets
11/21/2024	$8.00	Underweight	Morgan Stanley
9/23/2024		Overweight → Neutral	Cantor Fitzgerald
4/15/2024	$45.00	Overweight	Barclays
4/15/2024	$459.00	Overweight	Barclays
2/7/2024	$81.00	Buy	Goldman
10/26/2023	$25.00	Outperform	RBC Capital Mkts
10/24/2023	$32.00	Overweight	Cantor Fitzgerald